Pomegra
UK startup Basecamp Research closed a $140M Series C at an $800M valuation, with Anthropic and Nvidia joining lead investor S32 to back its AI-designed cell therapy push.
Key Takeaways:
- The $140M Series C values Basecamp at $800M, more than triple its previous known valuation, in a round described as oversubscribed.
- S32 led the round; Anthropic's Anthology Fund and Nvidia's NVentures joined as new investors alongside a dozen-plus other backers.
- All six of Basecamp's therapy programs remain preclinical; the funding is explicitly intended to move at least one into clinical trials.
Lead
Basecamp Research, the London-based startup that builds biological AI models from biodiversity-derived genomic data, raised $140M in Series C financing on September 23, 2026. The round was led by S32, the California venture firm founded by Google Ventures alumnus Bill Maris. Anthropic's Anthology Fund - a vehicle co-managed with Menlo Ventures - and Nvidia's NVentures joined as new investors. Returning backers Singular and True Ventures also participated, along with Catalio Capital Management, the NATO Innovation Fund, The Rockefeller Foundation, and several others. Total funding raised to date stands at $225M.
What Does Basecamp Research Actually Build?
EDEN is the central product: a 28-billion-parameter biological foundation model trained on the Trillion Gene Atlas, a proprietary genomic dataset assembled through partnerships in more than 30 countries. Most AI drug discovery firms train on public databases of human or common model-organism DNA. Basecamp has spent six years collecting sequences from rare and extremophile organisms - environments that have produced molecular solutions not found in conventional genomic libraries. That data collection strategy is the company's stated moat.
EDEN uses that training corpus to design long, complex DNA sequences for therapeutic applications. The company pairs EDEN's design capability with large serine recombinases, enzymes that integrate custom DNA into a cell's genome at precise locations. The primary application currently in development is in vivo cell therapy: reprogramming a patient's cells inside the body rather than extracting and modifying them externally, which is how most approved cell therapies work today.
Why Did Anthropic and Nvidia Join This Round?
Both investors have structural reasons to back biology foundation models. Nvidia's NVentures has placed bets across the AI drug discovery space as compute-intensive biological modeling grows into one of the heavier workloads in the sector. For Anthropic, the Anthology Fund - its joint investment vehicle with Menlo Ventures - targets high-parameter AI applications beyond the pure software stack. A 28-billion-parameter model purpose-built for therapeutic design sits squarely within that scope. Neither firm disclosed the size of its individual stake.
The participation of two AI infrastructure heavyweights signals more than capital. It reflects a broader conviction among model developers that biological sequence design is converging toward the same scaling dynamics that drove progress in language and image models.
Six Programs, Still Preclinical
Basecamp is advancing six therapy programs targeting cancer and autoimmune conditions. The company has not published peer-reviewed results for each program, and all remain in preclinical stages. The $140M is earmarked to train a new generation of EDEN models and push at least one program - in vivo cell therapy first - into clinical development.
That step is the hardest one. The path from AI-designed DNA sequences to a clinical trial involves biological validation across multiple species, regulatory filings, and manufacturing processes that have stalled or ended better-funded programs before. Basecamp's platform claims are plausible in concept; they are not yet validated in human trials.
What Does the $800M Valuation Say About This Stage?
The company's prior known valuation was less than a quarter of $800M. An oversubscribed round at more than triple the previous price signals strong investor demand, but it also embeds considerable speculation about future clinical outcomes. Basecamp is pricing in platform optionality - the value of EDEN as a generalizable tool across multiple disease areas - not a revenue line or a Phase 1 readout.
S32 set the price as lead. That the round was oversubscribed suggests Maris had room to be selective about co-investors. The inclusion of Anthropic and Nvidia brings strategic weight alongside capital.
Outlook
With $225M in total funding and a freshly anchored $800M valuation, Basecamp Research enters the next phase with a well-resourced balance sheet and a high-profile investor base. The company's near-term credibility test is moving an EDEN-designed therapy into human trials - a milestone that would shift the narrative from platform promise to clinical evidence. The Trillion Gene Atlas data strategy may prove durable or may be replicated as biodiversity genomics becomes more accessible. Either way, S32, Anthropic's fund, and Nvidia have collectively concluded that the question is worth $140M to answer.
